Provider review

Zappy Health review: pricing, pharmacy, and evidence status

Released: · Last reviewed: · By Dr. Parmis

Zappy Health offers GLP-1 medications through telehealth. Every price, credential and pharmacy claim below is labeled by evidence status and read date.

Zappy Health's lowest price on file is $209/month (6-month plan), read November 20, 2026 on its own page. It does not name a dispensing pharmacy. On November 20, 2026 it scored 68.1/100 on GLP Ranked's v4.1 rubric, #6 of 15.

Rank and score

Zappy Health scores 68.1 of 100, #6 of 15 scored programs (November 20, 2026). The table shows every sub-check, the points earned and why; the methodology explains each one.

Zappy Health: v4.1 sub-checks, points earned and notes (read November 20-21, 2026)
IDCategorySub-checkPointsNote
PT1Pricing transparencyDrug price printed on the program's own page, read in the November 20, 2026 re-read5 of 5
PT2Pricing transparencyPrice includes medication and care, or every required fee is printed beside it (2 if the program's own figures disagree)5 of 5
PT3Pricing transparencyPrice at every dose knowable: same price at every dose, or a full dose ladder5 of 5
PT4Pricing transparencyPlan term and billing interval stated (2 if the program's own pages disagree)5 of 5
CO1Clinical oversightPrescribing medical group named (9), network label (5), physician executive only (3), arrangement described (2)2 of 9
CO2Clinical oversightPrescribers' licensure or certification stated3 of 3
CO3Clinical oversightClinical lead (medical director or chief medical officer) named with credential0 of 3
PH1Pharmacy transparencyDispensing pharmacy named (10), class described but not named (4), described only (2); brand-only programs whose pages say prescriptions go to the pharmacy you choose (10)4 of 10'LegitScript-verified 503A compounding pharmacies', none named on the pages read 2026-11-21
PH2Pharmacy transparencyPharmacy class (503A/503B) or licensure stated; brand-only programs that send prescriptions to your chosen pharmacy (5)5 of 5
SU1SupportTwo or more contact channels published (4), one (2)4 of 4
SU2SupportHow to cancel is stated3 of 3
SU3SupportRefund terms are stated (any stated condition under which money is refunded or credited)3 of 3
RD1Regulatory disclosureCompounded products described as not FDA-approved; brand-only programs (5)5 of 5
RD2Regulatory disclosureNo open FDA warning letter in FDA's index (read November 20, 2026)0 of 5FDA warning letter 717991, February 20, 2026; no close-out posted
AC1AccessibilityWhere it operates stated clearly (4); vague or conflicting statements (2)4 of 4
AC2AccessibilityPayment beyond a card stated (HSA/FSA or pay-later)3 of 3
AC3AccessibilityCan start month to month without a multi-month commitment3 of 3
ANTotal annual costsemaglutide, 12 months: $2,508 (two 6-month plans: 2 × $1,254); benchmark $1,1409.1 of 2020 × benchmark ÷ cost
Total68.1 of 100

FDA record: FDA warning letter 717991, dated February 20, 2026 (False & Misleading Claims/Misbranded (Telehealth)). FDA's index showed no close-out letter when read on November 20, 2026. Under sub-check RD2 an open letter removes 5 points, for every program alike.

Strengths and limitations

Drawn from the sub-checks above, as read November 20-21, 2026.

  • Strength: Drug price printed on the program's own page, read in the November 20, 2026 re-read.
  • Strength: Price includes medication and care, or every required fee is printed beside it.
  • Strength: Price at every dose knowable: same price at every dose, or a full dose ladder.
  • Strength: Plan term and billing interval stated.
  • Limitation: Prescribing medical group named: 2 of 9.
  • Limitation: Clinical lead: 0 of 3.
  • Limitation: Dispensing pharmacy named: 4 of 10 ('LegitScript-verified 503A compounding pharmacies', none named on the pages read 2026-11-21).
  • Limitation: No open FDA warning letter in FDA's index: 0 of 5 (FDA warning letter 717991, February 20, 2026; no close-out posted).
  • Limitation: total annual cost scores 9.1 of 20.

Pricing by plan

Prices as stated on the provider's own published page unless marked otherwise. "Provider reported" means GLP Ranked has not independently reproduced the figure — see evidence status per row.
MedicationFormulationPlanPriceSourceEvidence
tirzepatidecompounded injectableMonth to month, no membership$349/moprovider page · read 2026-11-20Provider reported
tirzepatidecompounded injectable6-month plan$299/moprovider page · read 2026-11-20Provider reported
semaglutidecompounded injectableMonth to month, no membership$249/moprovider page · read 2026-11-20Provider reported
semaglutidecompounded injectable6-month plan$209/moprovider page · read 2026-11-20Provider reported

"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.

Clinical model

Described only: “The role of Zappy Health is limited to connecting users with independent healthcare providers and licensed Partner Pharmacies.” (zappyhealth.com, read 2026-11-10)

Accreditation: we have not verified any accreditation or certification claim for Zappy Health against the issuing body. If a program cites one (for example LegitScript), check the issuer's public lookup before you rely on it.

Pharmacy & compliance

Says a "LegitScript-verified 503A compounding pharmacy" makes its compounded medicines; no pharmacy is named on its product, FAQ or pharmacy pages (read 2026-11-21). On 2026-11-10 its compounded semaglutide page named The Pharmacy Hub. Pharmacy transparency is worth 15 of 100 points under our v4.1 rubric.

State availability

State-by-state availability is not independently verified.

Who this suits — and who it doesn't

Zappy Health may suit patients who want a standard-dose program and are comfortable proceeding without a named dispensing pharmacy disclosed up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying; ask the company for it.

Terms to check before you pay: whether cancellation and refund terms were found on its pages is recorded in sub-checks SU2 and SU3 above (read November 21, 2026); published support response times: not published.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Sources

  1. FDA warning letter 717991 (False & Misleading Claims/Misbranded (Telehealth)) — Regulator letter, captured 2026-11-20
  2. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026) — Regulator page, captured 2026-11-20
  3. FDA: Compounding: Inspections, Recalls, and other Actions (content current October 22, 2026) — Regulator list, captured 2026-11-21

Cite this page

GLP Ranked. "Zappy Health review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/zappy-health/

GLP Ranked. "Zappy Health review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/zappy-health/